Cerebrospinal Fluid Immunoglobulin Kappa Light Chain in Clinically Isolated Syndrome and Multiple Sclerosis

Background Oligoclonal bands (OCB) are the most widely used CSF test to support the diagnosis of MS and to predict conversion of clinically isolated syndrome (CIS) to multiple sclerosis (MS). Since OCB tests are based on non-quantitative and difficult to standardise techniques, measurement of immunoglobulin kappa free light chains (KFLC) may represent an easier to use quantitative test. Methods KFLC were measured in CSF and serum of 211 patients using ELISA. These include patients without any inflammatory central nervous system reaction (NIND, n = 77), MS (n = 20), viral CNS infections (V-CNS-I, n = 10), neuroborreliosis (NB, n = 17) and other bacterial CNS infections (B-CNS-I, n = 10). Furthermore a cohort of 77 patients with CIS, including 39 patients that remained CIS over follow-up of two years (CIS-CIS) and 38 patients that developed MS over the same follow-up time (CIS-MS). Results CSF-serum ratio of KFLC (Q KFLC) was elevated in all patients with MS, 86.8% of patients with CIS-MS and 61.5% of patients with CIS-CIS. It was significantly elevated in CIS with presence of OCB (p<0.001). Q KFLC significantly correlated with other CSF variables such as CSF leukocyte count (p<0.001, R = 0.46), CSF CXCL13 levels (p<0.001, R = 0.64) and also intrathecal IgG synthesis (p<0.001, R = 0.74) as determined by nephelometry and quotient diagram. OCB were detected in 66.7% of CIS-CIS and in 92.1% of CIS-MS. Conclusions Although the measurement of CSF KFLC is a rapid and quantitative easy to standardize tool, it is almost equal but not superior to OCB with regard to diagnostic sensitivity and specificity in patients with early MS.

[1]  A. Petzold Intrathecal oligoclonal IgG synthesis in multiple sclerosis , 2013, Journal of Neuroimmunology.

[2]  E. Meinl,et al.  The utility of cerebrospinal fluid analysis in patients with multiple sclerosis , 2013, Nature Reviews Neurology.

[3]  U. Rot,et al.  Comparison of two methods for the detection of oligoclonal bands in a large number of clinically isolated syndrome and multiple sclerosis patients , 2012, Clinical Neurology and Neurosurgery.

[4]  H. Hartung,et al.  Revised McDonald criteria: The persisting importance of cerebrospinal fluid analysis , 2011, Annals of neurology.

[5]  M. Krumbholz,et al.  Humoral autoimmunity in multiple sclerosis , 2011, Journal of the Neurological Sciences.

[6]  B. Sela,et al.  Immunoglobulin Free Light Chain Dimers in Human Diseases , 2011, TheScientificWorldJournal.

[7]  Jeffrey A. Cohen,et al.  Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria , 2011, Annals of neurology.

[8]  A. Moulignier,et al.  Prognostic value of cerebrospinal fluid analysis at the time of a first demyelinating event , 2011, Multiple sclerosis.

[9]  B. Sela,et al.  Free light chain monomers in the diagnosis of multiple sclerosis , 2010, Journal of Neuroimmunology.

[10]  J. Álvarez-cermeño,et al.  The risk of relapse after a clinically isolated syndrome is related to the pattern of oligoclonal bands , 2010, Journal of Neuroimmunology.

[11]  J. Kassubek,et al.  The Chemokine CXCL13 Is a Prognostic Marker in Clinically Isolated Syndrome (CIS) , 2010, PloS one.

[12]  M. Mühlau,et al.  The radiologically isolated syndrome: take action when the unexpected is uncovered? , 2010, Journal of Neurology.

[13]  À. Rovira,et al.  Cerebrospinal fluid chitinase 3-like 1 levels are associated with conversion to multiple sclerosis. , 2010, Brain : a journal of neurology.

[14]  A. Ludolph,et al.  The chemokine CXCL13 in acute neuroborreliosis , 2009, Journal of Neurology, Neurosurgery & Psychiatry.

[15]  J. Fleming,et al.  A consensus protocol for the standardization of cerebrospinal fluid collection and biobanking , 2009, Neurology.

[16]  A. Ludolph,et al.  IgG Antibodies against Measles, Rubella, and Varicella Zoster Virus Predict Conversion to Multiple Sclerosis in Clinically Isolated Syndrome , 2009, PloS one.

[17]  D. Goodin,et al.  Review: Treatment of early multiple sclerosis: the value of treatment initiation after a first clinical episode , 2009, Multiple sclerosis.

[18]  H. Hartung,et al.  Cerebrospinal fluid biomarkers in multiple sclerosis , 2009, Neurobiology of Disease.

[19]  F. Birklein,et al.  High sensitivity of free lambda and free kappa light chains for detection of intrathecal immunoglobulin synthesis in cerebrospinal fluid , 2009, Acta neurologica Scandinavica.

[20]  T. Brücke,et al.  Elevated levels of kappa free light chains in CSF support the diagnosis of multiple sclerosis , 2008, Journal of Neurology.

[21]  A. Rovira,et al.  Do oligoclonal bands add information to MRI in first attacks of multiple sclerosis? , 2008, Neurology.

[22]  Francesco Lolli,et al.  Interlaboratory reproducibility of isoelectric focusing in oligoclonal band detection. , 2007, Clinical chemistry.

[23]  B. Thrower Clinically isolated syndromes , 2007, Neurology.

[24]  G. Giovannoni Multiple Sclerosis Cerebrospinal Fluid Biomarkers , 2006, Disease markers.

[25]  H. Link,et al.  Oligoclonal bands in multiple sclerosis cerebrospinal fluid: An update on methodology and clinical usefulness , 2006, Journal of Neuroimmunology.

[26]  M. Krumbholz,et al.  B lineage cells in the inflammatory central nervous system environment: Migration, maintenance, local antibody production, and therapeutic modulation , 2006, Annals of neurology.

[27]  A. Kraneveld,et al.  Free immunoglobulin light chains as target in the treatment of chronic inflammatory diseases. , 2006, European journal of pharmacology.

[28]  D. Bernard,et al.  Quantification of Immunoglobulin Free Light Chains in CerebroSpinal Fluid by Nephelometry , 2005, Journal of Clinical Immunology.

[29]  K. Lackner,et al.  Kappa free light chains in cerebrospinal fluid as markers of intrathecal immunoglobulin synthesis. , 2004, Clinical chemistry.

[30]  L. Benson,et al.  Trimolecular Complexes of λ Light Chain Dimers in Serum of a Patient with Multiple Myeloma , 2002 .

[31]  M. Drayson,et al.  Highly sensitive, automated immunoassay for immunoglobulin free light chains in serum and urine. , 2001, Clinical chemistry.

[32]  Hansotto Reiber,et al.  Cerebrospinal fluid analysis: disease-related data patterns and evaluation programs , 2001, Journal of the Neurological Sciences.

[33]  Hansotto Reiber,et al.  Reporting Cerebrospinal Fluid Data: Knowledge Base and Interpretation Software , 2001, Clinical chemistry and laboratory medicine.

[34]  M. Krakauer,et al.  Intrathecal synthesis of free immunoglobulin light chains in multiple sclerosis , 1998, Acta neurologica Scandinavica.

[35]  G. Comi,et al.  Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis. , 1997, Brain : a journal of neurology.

[36]  K. Lamers,et al.  Cerebrospinal fluid free kappa light chains versus IgG findings in neurological disorders: qualitative and quantitative measurements , 1995, Journal of Neuroimmunology.

[37]  G. Bernardi,et al.  Cerebrospinal fluid in the diagnosis of multiple sclerosis: a consensus report. , 1994, Journal of neurology, neurosurgery, and psychiatry.

[38]  R. Newcombe Confidence intervals: enlightening or mystifying? , 1992, BMJ.

[39]  E. Thompson,et al.  Isoelectric Focusing of Cerebrospinal Fluid Immunoglobulin G: An Annotated Update , 1990, Annals of clinical biochemistry.

[40]  R. Rudick,et al.  Relative diagnostic value of cerebrospinal fluid kappa chains in MS , 1989, Neurology.

[41]  C. Laterre,et al.  Free kappa and lambda light chain levels in the cerebrospinal fluid of patients with multiple sclerosis and other neurological diseases , 1988, Journal of Neuroimmunology.

[42]  C. DeCarli,et al.  Free light chains in multiple sclerosis and infections of the CNS , 1987, Neurology.

[43]  J. E. Hopper,et al.  Evidence by radioimmunoassay that mitogen-activated human blood mononuclear cells secrete significant amounts of light chain Ig unassociated with heavy chain. , 1986, Cellular immunology.

[44]  J. Kurtzke Rating neurologic impairment in multiple sclerosis , 1983, Neurology.

[45]  K. Felgenhauer,et al.  Evaluation of the blood-CSF barrier by protein gradients and the humoral immune response within the central nervous system , 1976, Journal of the Neurological Sciences.

[46]  L. Benson,et al.  Trimolecular complexes of lambda light chain dimers in serum of a patient with multiple myeloma. , 2002, Clinical chemistry.

[47]  A. Solomon,et al.  Differences in kappa to lambda (kappa:lambda) ratios of serum and urinary free light chains. , 1998, Clinical and experimental immunology.